How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 53.9 | 53.9 | 56.3 | 53.8 | 53.8 | 50.4 | -3.5 |
| Healthcare | 40.3 | 40.3 | 37.7 | 39.8 | 39.8 | 41.6 | +1.3 |
| Chemicals | 3.3 | 3.3 | 5.0 | 4.0 | 4.0 | 4.2 | +0.8 |
| FMCG | · | · | · | 1.3 | 1.3 | 1.2 | -0.1 |
| Financial Services | · | · | 0.6 | 0.4 | 0.4 | · | -0.2 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.51% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| MAXHEALTH | Healthcare | 5.68% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| DIVISLAB | Pharma | 5.12% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| ABBOTINDIA | Pharma | 4.97% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| CIPLA | Pharma | 4.77% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| APOLLOHOSP | Healthcare | 4.61% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| RAINBOW | Healthcare | 4.42% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| DRREDDY | Pharma | 4.26% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| GLAXO | Healthcare | 4.12% | 6 | 7 | 2 | 6 | 7 | 0/2 | +1.2% |
| MANKIND | Pharma | 3.85% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| FORTIS | Healthcare | 3.35% | 8 | 8 | 5 | 2 | 3 | 0/2 | +8.9% |
| BAYERCROP | Chemicals | 3.20% | 2 | 4 | — | 4 | 8 | 0/2 | -17.5% |
| LUPIN | Pharma | 2.81% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| SYNGENE | Healthcare | 2.73% | 2 | 3 | 6 | 9 | 7 | 0/2 | -0.6% |
| ALKEM | Pharma | 2.64% | 9 | 8 | 8 | 10 | 6 | 1/2 | +0.5% |
| SAILIFE | Healthcare | 2.53% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| PFIZER | Healthcare | 2.50% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| MEDANTA | Healthcare | 2.32% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| CONCORDBIO | Pharma | 1.76% | 5 | 4 | 2 | 1 | 4 | 0/2 | +19.8% |
| LALPATHLAB | Healthcare | 1.64% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| NEULANDLAB | Healthcare | 1.60% | 10 | 10 | 5 | 10 | 2 | 1/2 | +27.4% |
| AJANTPHARM | Pharma | 1.60% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| GILLETTE | FMCG | 1.23% | 3 | 7 | 1 | 6 | 6 | 0/2 | -2.2% |
| TORNTPHARM | Pharma | 1.02% | 10 | 8 | 5 | 6 | 1 | 1/2 | +14.6% |
| SUMICHEM | Chemicals | 0.97% | 6 | 7 | 1 | 2 | 3 | 0/2 | +11.7% |
| JUBLPHARMA | Pharma | 0.91% | 5 | 2 | 3 | 6 | 6 | 0/2 | +5.5% |
| IPCALAB | Pharma | 0.58% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹187 (+87%), vs ₹169 for Nifty 500 (+69%) and ₹152 for Nifty 50 (+52%). Its relative-strength line ended at 123 vs Nifty 50 and 110 vs Nifty 500 — above 100, sustained outperformance.